The SOLOIST-WHF trial investigated the efficacy of sotagliflozin, a dual SGLT2 and SGLT1 inhibitor, in patients with type 2 diabetes and a recent hospitalization for worsening HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.